Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

real-time surveillance

- PMLiVE

EMA concludes GSK, Vir’s mAb can be used to treat high-risk COVID-19 patients

Recommendations can be used to support national advice prior to marketing authorisation

- PMLiVE

AZ, Pfizer/BioNTech COVID-19 vaccines ‘highly effective’ against Indian variant

UK study finds vaccines are likely to be effective in preventing hospitalisation/death

- PMLiVE

Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab

Trial will enrol 600 adults, aged 65 and older, from the phase 3 Pfizer/BioNTech COVID-19 vaccine trial

Improving Public Health Through Telemedicine

Laurence Girard, CEO of Fruit Street Health, shares his tips for aspiring HealthTech entrepreneurs, his views on the future of telemedicine and digital health, and why he thinks healthcare companies...

Impetus Digital

Social Media, Wearable Technologies, and AI

João Bocas, CEO, Keynote Speaker, Social Media Influencer & Advisor at Digital Salutem, shares his thoughts on several intriguing topics related to wearables, AI, machine learning, robotics, and other digital...

Impetus Digital

Advancing Human Health Through Precise Measures of Movement, Cognition, & Biometrics

Scott McMillan, CEO of XCO, discusses wearable technologies for chronic and acute disease monitoring, virtual trials, and assessment of athlete performance. Among other things, we also dive into the role...

Impetus Digital

- PMLiVE

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

SGLT2 inhibitor failed to significantly reduce the number of patients who experienced organ failure or died compared to placebo

- PMLiVE

GSK and Medicago’s COVID-19 vaccine shows promising antibody responses in phase 2

Neutralising antibody responses in vaccinated participants were about ten times higher than those seen in a panel of sera from recovering COVID-19 patients

- PMLiVE

Detailed results for Regeneron’s antibody cocktail continue to show benefit in high-risk COVID-19 outpatients

Treatment shortened symptom duration and reduced viral load in non-hospitalised patients with COVID-19

- PMLiVE

Sanofi, GSK’s COVID-19 vaccine generates strong immune responses across all age groups

Sanofi/GSK delayed their COVID-19 vaccine programme in December 2020 after the vaccine candidate induced low immune responses in older adults

- PMLiVE

Positive results for GSK/CureVac’s COVID-19 vaccine

Vaccine candidate generated strong immune responses in preclinical testing

How to Simplify Genetics & Raise Awareness Around Orphan Diseases

Dr. Gail Ouellette, President and Scientific Director of Regroupement Québécois des Maladies Orphelines (RQMO)/Quebec Coalition of Orphan Diseases and Creator of the “Genetics Simply" website, shares her thoughts on the...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links